Company / SG&A per Share
Lilly (Eli) SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$12.28
FY2025
5-year range
$6.64 / $12.28
FY2021-FY2025
Trend
+29.3%
vs FY2024
Sector context
#11 of 210
Health Care
What the data says
Among 210 Health Care companies, Lilly (Eli) is in the bottom 5% for sg&a per share. SG&A per Share has increased for 5 consecutive years, from $5.78 in FY2020 to $12.28 in FY2025.
Based on SEC 10-K filings.
12.28 in FY2025 with a 5-year CAGR of +16.3%. Top quartile in the Health Care sector.
Increased from $7.05 to $12.28 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +22.3%
- 5-Year CAGR
- +16.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 210This company $12.28 Sector average $29.50
▼
-58.4% below sector average
Key checks
Key Insights
- Lilly (Eli)'s sg&a per share has grown for 5 consecutive years.
- In FY2025, sg&a per share increased 29.3% year-over-year.
- Ranks #11 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.28 | +29.3% |
| FY2024 | $9.50 | +34.7% |
| FY2023 | $7.05 | +5.2% |
| FY2022 | $6.71 | +1.0% |
| FY2021 | $6.64 | +14.9% |
| FY2020 | $5.78 | -2.1% |
| FY2019 | $5.91 | +5.0% |
| FY2018 | $5.63 | -8.2% |
| FY2017 | $6.13 | +0.9% |
| FY2016 | $6.08 | +0.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026